Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
In 2024, the Canadian Cancer Statistics publication was developed in the form of a peer-reviewed article "Projected estimates of cancer in Canada in 2024” published in the Canadian Medical Association Journal (CMAJ).
Another successful CCTG Spring Meeting of Participants ended with ~900 network members, international friends and sponsors contributing to sessions and workshops to propose new trials and review current portfolio of activities. It was hectic but also inspirational.
A longer follow-up from the PR13/RADICALS-RT international study confirms that having radiotherapy only if the cancer returns, as opposed to having it soon after surgery, is a better approach for most people.
Findings from the CCTG PR13/RADICALS-HD study confirm that adding two years, compared to six months of hormone therapy delays prostate cancer spread in people who had surgery to remove the prostate followed by radiotherapy.
BRC2 (E1505): A phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/= 4 cm) – III a non-small cell lung cancer (NSCLC) trial. NCT00324805: Results are available on www.clinicaltrials.gov
Congratulations to Sharon Turnell who was presented the CCTG Excellence in Clinical Trials Conduct Award at the CCTG Spring Meeting for her continued excellence in clinical trial operations and compliance at her home institution, Saint John Regional Hospital.
The Phase III Team Award for Intergroup-Led Trials was presented to the ME15 Team at Odette Cancer Centre (Sunnybrook Health Sciences Centre) at the CCTG Spring Meeting this weekend. The team members include, Dr. Frances Wright (QI), Roxana Marmolejo, Christina Siwak.
"We are absolutely thrilled to be the recipients of this CCTG Phase III Team Award. We have a fantastic team who work extremely hard to provide our patients with the option of participating in this potentially practice-changing trial, MelMart, the melanoma margins trial."